<div id="readability-page-1"><div><ul> <li>LivaNova PLC recently elected experienced global executive Jette Nygaard-Andersen to its Board of Directors and appointed Anne Liddy as Chief Legal Officer, while long-serving director Dr. Sharon O’Kane stepped down after a decade on the Board.</li> <li>These governance changes bring fresh expertise in medtech, legal and compliance oversight, and executive leadership, potentially influencing how LivaNova manages regulatory complexity and long-term corporate priorities.</li> <li>We’ll now examine how adding Nygaard-Andersen’s medtech board experience may shape LivaNova’s existing investment narrative and future risk profile.</li> </ul><p>Find 44 companies with promising cash flow potential yet trading below their fair value.</p><h2>LivaNova Investment Narrative Recap</h2><p>To own LivaNova, you need to believe in its ability to grow neuromodulation and cardiopulmonary franchises while managing regulatory and reimbursement complexity. The latest board and legal leadership changes mainly strengthen governance and oversight; they do not appear to materially alter the key near term catalyst of execution in core therapies or the biggest risk around pricing pressure and high ongoing R&amp;D needs.</p> <p>Among the recent announcements, Anne Liddy’s appointment as Chief Legal Officer stands out here. Given LivaNova’s exposure to global healthcare regulations, reimbursement decisions, and product approvals, an experienced legal and compliance leader is closely tied to whether the company can convert its clinical pipeline into commercial results while containing regulatory, product safety, and supply chain risks that could disrupt revenue and margins.</p> <p>Yet behind the recent governance upgrades, investors still need to watch the risk that payer cost controls could eventually constrain LivaNova’s premium therapies...</p> <p>Read the full narrative on LivaNova (it's free!)</p><p>LivaNova's narrative projects $1.8 billion revenue and $220.8 million earnings by 2029. This requires 7.4% yearly revenue growth and a $113.7 million earnings increase from $107.1 million today.</p><p>Uncover how LivaNova's forecasts yield a $80.60 fair value, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c4258a7-0182-4814-9995-c80a9d257cb7/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/2c4258a7-0182-4814-9995-c80a9d257cb7/chart/quote-price"/><figcaption>LIVN 1-Year Stock Price Chart</figcaption></figure> <p>Before this news, the most optimistic analysts were assuming revenue of about US$1.6 billion and earnings of roughly US$261 million by 2028, a far more upbeat view than the baseline. Depending on how you see new leadership affecting regulatory timelines and cost pressures, you might lean toward that bullish story or a more cautious one that highlights the risk of slower approvals and tighter reimbursement.</p><p>Explore 2 other fair value estimates on LivaNova - why the stock might be worth as much as 15% more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your LivaNova research is our analysis highlighting 3 key rewards that could impact your investment decision.</li><li>Our free LivaNova research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LivaNova's overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.</li><li>Outshine the giants: these 14 early-stage AI stocks could fund your retirement.</li><li>Uncover the next big thing with 24 elite penny stocks that balance risk and reward.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><div><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies</p><p>Or build your own from over 50 metrics.</p></div><p>Explore Now for Free</p></div></div></div>

LIVN

<p>LivaNova PLC appointed Jette Nygaard-Andersen to its Board and Anne Liddy as Chief Legal Officer, while Dr. Sharon O’Kane stepped down. These governance changes aim to strengthen oversight in medtech, legal, and compliance areas, potentially aiding regulatory management. However, the core investment narrative remains focused on neuromodulation growth and managing pricing pressures, with analysts projecting $1.8 billion revenue by 2029.</p>

Is LivaNova’s (LIVN) Boardroom Refresh Quietly Reframing Its Long-Term Risk and Strategy Playbook?